SABCS 2021 Meeting News Preview - 12

Seeing Deeper into Recurrent
or Metastatic Breast Cancer
Cerianna-the only imaging agent that detects whole-body ER+ lesion status1,2
Cerianna (fluoroestradiol F18) injection, a targeted radiopharmaceutical, for use with positron emission tomography (PET) imaging
for the detection of estrogen receptor positive (ER+) lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.1
You are invited to attend a Product Theater sponsored
by GE Healthcare at the 2021 SABCS®
1. Learn about the clinical implications of Estrogen Receptor discordance
2. Understand the mechanism of Cerianna PET imaging
3. Recognize the clinical applications of Cerianna PET imaging
4. Identify patients who may benefit from Cerianna PET imaging
Location Product Theater, Exhibit Floor
Time 10 am
Date Tuesday, December 7, 2021
Speakers:
Gary Ulaner, MD, PhD, FACNM
James & Pamela Muzzy Endowed Chair in Molecular Imaging
and Therapy, Hoag Family Cancer Institute
Hannah Linden, MD
Professor, Division of Medical Oncology, University of
Washington School of Medicine
Professor, Clinical Research Division, Fred Hutchinson Cancer
Research Center
Sponsored by GE Healthcare
This Exhibitor Product Theater is a promotional activity and is not approved for continuing education
credit. The content of the Exhibitor Product Theater and opinions expressed by presenters are those
of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium®
(SABCS®
).
Important Safety Information
Indications and Usage
CERIANNA is indicated for use with positron emission tomography
(PET) imaging for the detection of estrogen receptor (ER)-positive
lesions as an adjunct to biopsy in patients with recurrent or
metastatic breast cancer.
Cerianna.com
Limitations of Use
Tissue biopsy should be used to confirm recurrence of breast cancer
and to verify ER status by pathology. CERIANNA is not useful for
imaging other receptors, such as human epidermal growth factor
receptor 2 (HER2) and the progesterone receptor (PR).
Contraindications
None.
Adverse Reactions
In Clinical Trials (n=1207) the most common adverse reactions seen
occurred at a rate <1%: were injection-site pain and dysgeusia.
For full Prescribing Information click on or visit http://cerianna.com/pi.
To report SUSPECTED ADVERSE REACTIONS, contact Zionexa
US Corp, a GE Healthcare Company at +1.844.946.6392 or FDA
at 1-800-FDA-1088 or www.fda.gov/medwatch.
References: 1. Cerianna (fluoroestradiol F 18) Injection Prescribing Information. Zionexa US Corp, 2020 2. Kurland BF, et al.
Oncologist. 2020;25(10):835-844.
© GE, 2021
GE, the GE Monogram, and Cerianna are trademarks of GE
Any third-party trademarks are property of their respective owners.
November 2021 JB06004US
http://www.Cerianna.com http://www.cerianna.com/pi

SABCS 2021 Meeting News Preview

Table of Contents for the Digital Edition of SABCS 2021 Meeting News Preview

SABCS 2021 Meeting News Preview - Cover
SABCS 2021 Meeting News Preview - 2
SABCS 2021 Meeting News Preview - A
SABCS 2021 Meeting News Preview - B
SABCS 2021 Meeting News Preview - 3
SABCS 2021 Meeting News Preview - 4
SABCS 2021 Meeting News Preview - 5
SABCS 2021 Meeting News Preview - 6
SABCS 2021 Meeting News Preview - 7
SABCS 2021 Meeting News Preview - 8
SABCS 2021 Meeting News Preview - 9
SABCS 2021 Meeting News Preview - 10
SABCS 2021 Meeting News Preview - 11
SABCS 2021 Meeting News Preview - 12
https://www.nxtbookmedia.com